Literature DB >> 1682252

Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon.

J M Beck1, H D Liggitt, E N Brunette, H J Fuchs, J E Shellito, R J Debs.   

Abstract

Pneumocystis carinii pneumonia in patients with AIDS may result from impaired local release of gamma interferon from lung lymphocytes and subsequent failure of macrophage activation. We tested this hypothesis with mice rendered immunodeficient by selective depletion of CD4+ lymphocytes and inoculated intratracheally with P. carinii. After aerosol administration of recombinant murine gamma interferon, the intensity of P. carinii infection in these mice was reduced in comparison with that in mice not treated with gamma interferon. Histologic scoring of lung tissue did not reveal additional pulmonary inflammation attributable to gamma interferon. Aerosol administration of gamma interferon may reduce the intensity of P. carinii infection by augmentation of host defense, despite persistent CD4+ lymphocyte depletion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682252      PMCID: PMC258968          DOI: 10.1128/iai.59.11.3859-3862.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Characterization of bronchoalveolar lymphocytes during a specific antibody-forming cell response in the lungs of mice.

Authors:  J L Curtis; H B Kaltreider
Journal:  Am Rev Respir Dis       Date:  1989-02

2.  Uptake and degradation of Pneumocystis carinii by macrophages in vitro.

Authors:  L A Von Behren; E L Pesanti
Journal:  Am Rev Respir Dis       Date:  1978-12

3.  Modulation of pulmonary macrophage superoxide release and tumoricidal activity following activation by biological response modifiers.

Authors:  D B Drath
Journal:  Immunopharmacology       Date:  1986-10

4.  Interferon-gamma increases alveolar macrophage Ia antigen expression despite oral administration of dexamethasone to rats.

Authors:  H J Fuchs; C W Czarniecki; H H Chiu; M Sniezek; J E Shellito
Journal:  Am J Respir Cell Mol Biol       Date:  1989-12       Impact factor: 6.914

5.  T4+ cell production of interferon gamma and the clinical spectrum of patients at risk for and with acquired immunodeficiency syndrome.

Authors:  H W Murray; D A Scavuzzo; C D Kelly; B Y Rubin; R B Roberts
Journal:  Arch Intern Med       Date:  1988-07

6.  Correlation of in vitro immune defects with impaired gamma interferon response in human-immunodeficiency-virus-infected individuals.

Authors:  T Rudy; G Opelz; R Gerlach; V Daniel; K Schimpf
Journal:  Vox Sang       Date:  1988       Impact factor: 2.144

7.  Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats.

Authors:  R J Debs; H J Fuchs; R Philip; A B Montgomery; E N Brunette; D Liggitt; J S Patton; J E Shellito
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

8.  Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma.

Authors:  H W Murray; R A Gellene; D M Libby; C D Rothermel; B Y Rubin
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

Review 9.  NIH conference. Pneumocystis pneumonia: from bench to clinic.

Authors:  H Masur; H C Lane; J A Kovacs; C J Allegra; J C Edman
Journal:  Ann Intern Med       Date:  1989-11-15       Impact factor: 25.391

10.  The interaction in vitro of Pneumocystis carinii with macrophages and L-cells.

Authors:  H Masur; T C Jones
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

View more
  28 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 2.  Prevention of nosocomial bacterial pneumonia.

Authors:  J L Vincent
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

3.  Alveolar macrophages in neonatal mice are inherently unresponsive to Pneumocystis murina infection.

Authors:  Cathryn Kurkjian; Melissa Hollifield; J Louise Lines; Amy Rogosky; Kerry M Empey; Mahboob Qureshi; Stephen A Brown; Beth A Garvy
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

4.  Increased host resistance against Pneumocystis carinii pneumonia in gammadelta T-cell-deficient mice: protective role of gamma interferon and CD8(+) T cells.

Authors:  Chad Steele; Mingquan Zheng; Erana Young; Luis Marrero; Judd E Shellito; Jay K Kolls
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 5.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 6.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

Review 7.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Fatty acid nitroalkenes inhibit the inflammatory response to bleomycin-mediated lung injury.

Authors:  Melissa L Wilkinson; Elena Abramova; Changjiang Guo; James G Gow; Alexa Murray; Adolf Koudelka; Veronika Cechova; Bruce A Freeman; Andrew J Gow
Journal:  Toxicol Appl Pharmacol       Date:  2020-09-12       Impact factor: 4.219

9.  Neither neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis pneumonia in mice.

Authors:  Steve D Swain; Terry W Wright; Peter M Degel; Francis Gigliotti; Allen G Harmsen
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection.

Authors:  W Chen; E A Havell; A G Harmsen
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.